Literature DB >> 26672088

Infliximab for IPILIMUMAB-Related Colitis-Letter.

Edurne Arriola1, Matthew Wheater2, Ioannis Karydis3, Gareth Thomas3, Christian Ottensmeier3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26672088     DOI： 10.1158/1078-0432.CCR-15-2471

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  18 in total

Review 1.  The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.

Authors:  Arabella Young; Zoe Quandt; Jeffrey A Bluestone
Journal:  Cancer Immunol Res       Date:  2018-12       Impact factor: 11.151

Review 2.  Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

Authors:  Jordi Remon; Laura Mezquita; Jesús Corral; Noelia Vilariño; Noemi Reguart
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.

Authors:  Caroline Prieux-Klotz; Marie Dior; Diane Damotte; Johann Dreanic; Bertrand Brieau; Catherine Brezault; Vered Abitbol; Stanislas Chaussade; Romain Coriat
Journal:  Target Oncol       Date:  2017-06       Impact factor: 4.493

Review 4.  Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.

Authors:  Md Mominur Rahman; Tapan Behl; Md Rezaul Islam; Md Noor Alam; Md Mohaimenul Islam; Ali Albarrati; Mohammed Albratty; Abdulkarim M Meraya; Simona Gabriela Bungau
Journal:  Molecules       Date:  2022-06-13       Impact factor: 4.927

Review 5.  The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens.

Authors:  D W Vredevoogd; G Apriamashvili; D S Peeper
Journal:  Immunooncol Technol       Date:  2021-10-28

Review 6.  Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.

Authors:  Michael Dougan
Journal:  Curr Gastroenterol Rep       Date:  2020-03-17

Review 7.  Advances on immune-related adverse events associated with immune checkpoint inhibitors.

Authors:  Yong Fan; Yan Geng; Lin Shen; Zhuoli Zhang
Journal:  Front Med       Date:  2020-08-10       Impact factor: 4.592

Review 8.  Immune Checkpoint Inhibitor Toxicity.

Authors:  David J Palmieri; Matteo S Carlino
Journal:  Curr Oncol Rep       Date:  2018-07-31       Impact factor: 5.945

9.  Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.

Authors:  Jia Luo; Jason A Beattie; Paige Fuentes; Hira Rizvi; Jacklynn V Egger; Jeffrey A Kern; Donald Y M Leung; Mario E Lacouture; Mark G Kris; Maya Gambarin; Bianca D Santomasso; David M Faleck; Matthew D Hellmann
Journal:  J Thorac Oncol       Date:  2021-07-12       Impact factor: 20.121

10.  Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab.

Authors:  James L Alexander; Hajir Ibraheim; Bhavisha Sheth; Jessica Little; Muhammad Saheb Khan; Camellia Richards; Nikki Hunter; Dharmisha Chauhan; Raguprakash Ratnakumaran; Kathleen McHugh; David J Pinato; Paul Nathan; Julia Choy; Shanthini M Crusz; Andrew Furness; Samra Turajlic; Lisa Pickering; James Larkin; Julian P Teare; Sophie Papa; Ally Speight; Anand Sharma; Nick Powell
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.